Vol. 22/No. 02

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

Lori J. Wirth, MD, , discusses the potential impact of pralsetinib on the thyroid cancer treatment landscape.

Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.

Over the past 2 decades, a growing number of targetable tumor-specific molecular alterations have been identified, ushering in the era of precision oncology. Now, alterations in the RET gene can be added to the list of druggable targets.

The importance of objectively valid data is well established in clinical medicine. Such data include an accurate recording of a patient’s clinical history; evaluation of signs and symptoms of illness; and measurement of various routine indicators, such as granulocyte and platelet counts, serum glucose, electrolytes, and liver function tests.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Before New Year’s Day, millions of Americans had received the coronavirus disease 2019 vaccine, including frontline physicians and health care providers and nursing home patients, our most vulnerable citizens.